OliX Pharmaceuticals,Inc

KOSDAQ 226950.KQ

OliX Pharmaceuticals,Inc EBT Margin for the year ending December 31, 2023: -106.48%

OliX Pharmaceuticals,Inc EBT Margin is -106.48% for the year ending December 31, 2023, a 65.91% change year over year. EBT Ratio (Earnings Before Tax Ratio) is the fraction of earnings before taxes to total revenue, indicating the company's profitability before the impact of tax expenses.

OliX Pharmaceuticals,Inc EBT Margin for the year ending December 31, 2022 was -312.30%, a 61.75% change year over year.
OliX Pharmaceuticals,Inc EBT Margin for the year ending December 31, 2021 was -816.40%, a 1.52% change year over year.
OliX Pharmaceuticals,Inc EBT Margin for the year ending December 31, 2020 was -828.97%, a 34.22% change year over year.
OliX Pharmaceuticals,Inc EBT Margin for the year ending December 31, 2019 was -1,260.13%, a 50.85% change year over year.

Key data

Date	EBT Margin	Net Income Margin	EBITDA Margin	EBIT Margin

KOSDAQ: 226950.KQ

OliX Pharmaceuticals,Inc

CEO	Mr. Dong-Ki Lee Ph.D.
IPO Date	July 18, 2018
Location	South Korea
Headquarters	#1014 Gwanggyo Ace Tower1, 17
Employees	72
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Clinical Trials Drugstores & Retail Pharmacies Eyewear Vaccines

Description

OliX Pharmaceuticals, Inc., a clinical stage biotechnology company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company's products pipeline includes OLX101 for skin scar; OLX102 for skin whitening; OLX103, an atopic dermatitis product; OLX104 for hair loss; OLX105, an anti-wrinkle product; and OLX106 for diabetic foot ulcer. Its products pipeline also comprise OLX301 for age-related macular degeneration retinal fibrosis; OLX304 for retinitis pigmentosa; OLX201 for lung fibrosis; OLX202 for asthma; OLX203 for influenza; OLX401 for neuropathic pain; OLX701 for liver fibrosis; and OLX701 for cancer immunotherapy. The company has a collaboration agreement with Théa to develop SiRNA therapeutics for ophthalmic diseases; and a research collaboration with PCI Biotech Holding ASA. OliX Pharmaceuticals, Inc. was founded in 2010 and is based in Suwon, South Korea.

Key trends

Past 5 years